{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T10:47:24Z","timestamp":1782384444234,"version":"3.54.5"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T00:00:00Z","timestamp":1777766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T00:00:00Z","timestamp":1777766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40487-026-00437-8","type":"journal-article","created":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T21:06:47Z","timestamp":1777842407000},"page":"721-734","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study"],"prefix":"10.1007","volume":"14","author":[{"given":"Beno\u00eet","family":"Godbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Gobbini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaacoub","family":"Khalife","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Decroisette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Brellier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Lena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Fleuriet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeva","family":"Zysman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Egenod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,3]]},"reference":[{"key":"437_CR1","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1507643.","journal-title":"N Engl J Med"},{"key":"437_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1504627.","journal-title":"N Engl J Med"},{"key":"437_CR3","unstructured":"European Medicines Agency. OPDIVO (nivolumab): summary of product characteristics. 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/opdivo. Accessed 15 Apr 2025."},{"key":"437_CR4","doi-asserted-by":"publisher","first-page":"1744898","DOI":"10.1080\/2162402x.2020.1744898","volume":"9","author":"F Barlesi","year":"2020","unstructured":"Barlesi F, Dixmier A, Debieuvre D, et al. Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study. Oncoimmunology. 2020;9:1744898. https:\/\/doi.org\/10.1080\/2162402x.2020.1744898.","journal-title":"Oncoimmunology"},{"key":"437_CR5","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","volume":"34","author":"LE Hendriks","year":"2023","unstructured":"Hendriks LE, Kerr KM, Menis J, et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:358\u201376. https:\/\/doi.org\/10.1016\/j.annonc.2022.12.013.","journal-title":"Ann Oncol"},{"key":"437_CR6","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.3390\/biomedicines12122742","volume":"12","author":"F Colonese","year":"2024","unstructured":"Colonese F, Bulotta A, Genova C, et al. Immunotherapy in non-small-cell lung cancer: a modified Delphi survey consensus on first line treatment, special populations and rechallenge. Biomedicines. 2024;12:2742. https:\/\/doi.org\/10.3390\/biomedicines12122742.","journal-title":"Biomedicines"},{"key":"437_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.lungcan.2019.12.017","volume":"140","author":"M Giaj Levra","year":"2020","unstructured":"Giaj Levra M, Cott\u00e9 FE, Corre R, et al. Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: a national data base analysis. Lung Cancer. 2020;140:99\u2013106. https:\/\/doi.org\/10.1016\/j.lungcan.2019.12.017.","journal-title":"Lung Cancer"},{"key":"437_CR8","doi-asserted-by":"publisher","unstructured":"Gobbini E, Levra MG, P\u00e9rol M, et al. MA07.05 Immune checkpoint inhibitor (ICPi) re-challeng outcomes analysis in a French national cohort of non-small-cell lung cancer (NSCLC) patients. J Thorac Oncol. 2019;14:S274. https:\/\/doi.org\/10.1016\/j.jtho.2019.08.550.","DOI":"10.1016\/j.jtho.2019.08.550"},{"key":"437_CR9","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1038\/s41598-024-52034-2","volume":"14","author":"J Feng","year":"2024","unstructured":"Feng J, Chen X, Wei J, et al. Safety and efficacy of immune checkpoint inhibitor rechallenge in advanced non-small cell lung cancer: a retrospective study. Sci Rep. 2024;14:2315. https:\/\/doi.org\/10.1038\/s41598-024-52034-2.","journal-title":"Sci Rep"},{"key":"437_CR10","doi-asserted-by":"publisher","unstructured":"Godbert B, Zysman M, Gobbini E, et al. 1317P Real-world immunotherapy (IO) rechallenge outcomes with nivolumab (NIV) in advanced non-small cell lung cancer (aNSCLC) in France: LIST study interim results. Ann Oncol. 2024;35:S838\u20139. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.1373.","DOI":"10.1016\/j.annonc.2024.08.1373"},{"key":"437_CR11","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s40487-025-00381-z","volume":"13","author":"B Godbert","year":"2025","unstructured":"Godbert B, Gobbini E, Decroisette C, et al. Real-world use and immunotherapy rechallenge outcomes with nivolumab in advanced non-small cell lung cancer in France: interim results of the LIST study. Oncol Ther. 2025;13:1071\u201386. https:\/\/doi.org\/10.1007\/s40487-025-00381-z.","journal-title":"Oncol Ther"},{"key":"437_CR12","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1200\/jco.20.01605","volume":"39","author":"H Borghaei","year":"2021","unstructured":"Borghaei H, Gettinger S, Vokes EE, et al. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2021;39:723\u201333. https:\/\/doi.org\/10.1200\/jco.20.01605.","journal-title":"J Clin Oncol"},{"key":"437_CR13","doi-asserted-by":"publisher","first-page":"e497","DOI":"10.1016\/j.cllc.2020.04.013","volume":"21","author":"E Gobbini","year":"2020","unstructured":"Gobbini E, Toffart AC, P\u00e9rol M, et al. Immune checkpoint inhibitors rechallenge efficacy in non-small-cell lung cancer patients. Clin Lung Cancer. 2020;21:e497\u2013510. https:\/\/doi.org\/10.1016\/j.cllc.2020.04.013.","journal-title":"Clin Lung Cancer"},{"key":"437_CR14","doi-asserted-by":"publisher","first-page":"2492932","DOI":"10.1080\/2162402x.2025.2492932","volume":"14","author":"F Barlesi","year":"2025","unstructured":"Barlesi F, Dixmier A, Debieuvre D, et al. Final 3-year results from the EVIDENS study, an observational study of nivolumab in non-small cell lung cancer. Oncoimmunology. 2025;14:2492932. https:\/\/doi.org\/10.1080\/2162402x.2025.2492932.","journal-title":"Oncoimmunology"},{"key":"437_CR15","doi-asserted-by":"publisher","first-page":"106077","DOI":"10.1016\/j.intimp.2019.106077","volume":"78","author":"J Huang","year":"2020","unstructured":"Huang J, Zhang C, Wang Z, Ren S, Wang W. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level. Int Immunopharmacol. 2020;78:106077. https:\/\/doi.org\/10.1016\/j.intimp.2019.106077.","journal-title":"Int Immunopharmacol"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00437-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-026-00437-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00437-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T09:53:12Z","timestamp":1782381192000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-026-00437-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,3]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["437"],"URL":"https:\/\/doi.org\/10.1007\/s40487-026-00437-8","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,3]]},"assertion":[{"value":"6 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Beno\u00eet Godbert has received consulting and congress fees from AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, Regeneron, Roche and Sanofi. Elisa Gobbini has received speaker\u2019s bureau honoraria from Bristol Myers Squibb, Janssen, Merck Sharp & Dohme, Regeneron and Sanofi; and is the spouse of an AstraZeneca employee. Chantal Decroisette has participated in advisory boards for Amgen, AstraZeneca, Bristol Myers Squibb, Johnson and Johnson, Merck Sharp & Dohme, Pfizer, Regeneron, Roche and Takeda. Herv\u00e9 Lena has participated in advisory boards for Amgen, Bristol Myers Squibb, Merck Sharp & Dohme, Pfizer, Regeneron and Roche; and has received consulting and congress fees from AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, Pfizer, Roche and Takeda. Yaacoub Khalife, Florence Brellier and Anne Fleuriet are employees of and hold stock or stock options in Bristol Myers Squibb. Maeva Zysman has received grants and personal fees from Avadel Pharmaceuticals and Boehringer Ingelheim; personal fees from AstraZeneca, Chiesi, CSL Behring, GSK, Menarini and Sanofi; and financial support to attend meetings and\/or travel from AstraZeneca, Chiesi and GSK (unrelated to this work). Thomas Egenod has been an investigator in clinical trials sponsored by AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Merck Sharp & Dohme, Pfizer, Roche and Takeda; and has participated in advisory boards for AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Merck Sharp & Dohme, Pfizer, Roche and Takeda. Nicolas Girard has received research grants\/support from AbbVie, Amgen, AstraZeneca, Beigene, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Gilead, Hoffmann-La Roche, Janssen, LeoPharma, Lilly, Merk Serono, Merck Sharp & Dohme, Novartis, Sanofi and Sivan; has provided consulting services for AbbVie, Amgen, AstraZeneca, Beigene, Bristol Myers Squibb, Daiichi-Sankyo, Gilead, Ipsen Hoffmann-La Roche, Janssen, LeoPharma, Lilly, Merck Sharp & Dohme, Mirati, Novartis, Pfizer, Pierre Fabre, Sanofi, Sivan and Takeda; has participated on a data safety monitoring board for Hoffmann-La Roche; and reports the employment of a family member with AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the Helsinki Declaration of 1964 and its later amendments, the International Society for Pharmacoepidemiology (ISPE) Guidelines for Good Pharmacoepidemiology Practices (GPP) and applicable regulatory requirements. All required approvals from ethics committees, independent review committees, regulatory authorities and\/or other local governance bodies were obtained prior to study initiation (EudraCT\/ID RCB no. 2020-A00769-30). All patients provided oral informed consent and were permitted to withdraw from the study at any stage.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}